| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
MDXG
MiMedx Group
|
Apr 30, 2026 | BUY |
Strong Buy
+184.1% avg upside
17 analysts
|
$5.00
36.27% Upside
|
+7.3% |
|
LFMD
LifeMD
|
Jul 10, 2025 | BUY |
Strong Buy
+146.3% avg upside
13 analysts
|
$18.00
278.89% Upside
|
-63.8% |
|
TNDM
Tandem Diabetes Care
|
May 20, 2025 | BUY |
Buy
+116.0% avg upside
29 analysts
|
$75.00
390.27% Upside
|
-36.0% |
|
PIII
P3 Health Partners
|
May 16, 2025 | BUY |
Buy
+1767.0% avg upside
8 analysts
|
$20.00
86.14% Upside
|
+41.3% |
|
ELMD
Electromed
|
May 14, 2025 | BUY |
Strong Buy
-16.4% avg upside
6 analysts
|
$36.00
6.95% Downside
|
+29.8% |
|
RCEL
Avita Medical
|
May 09, 2025 | BUY |
Strong Buy
+154.7% avg upside
10 analysts
|
$14.00
249.12% Upside
|
-41.0% |
|
ASTH
Astrana Health
|
May 09, 2025 | BUY |
Strong Buy
+36.1% avg upside
16 analysts
|
$70.00
78.71% Upside
|
+32.3% |
|
ORGO
Organogenesis Holdings
|
May 09, 2025 | BUY |
Strong Buy
+375.4% avg upside
8 analysts
|
$5.00
104.89% Upside
|
-22.6% |
|
INFU
InfuSystem Holdings
|
May 08, 2025 | BUY |
Strong Buy
+52.9% avg upside
7 analysts
|
$12.50
32.67% Upside
|
+53.8% |
|
LFVN
LifeVantage
|
May 07, 2025 | BUY |
Strong Buy
+173.0% avg upside
3 analysts
|
$30.00
368.03% Upside
|
-54.0% |
|
BBNX
Beta Bionics, Inc.
|
May 07, 2025 | BUY |
Strong Buy
+51.9% avg upside
13 analysts
|
$30.00
116.09% Upside
|
-26.9% |
|
VMD
Viemed Healthcare
|
May 06, 2025 | BUY |
Strong Buy
+44.5% avg upside
2 analysts
|
$15.00
41.05% Upside
|
+15.1% |
|
ATEC
Alphatec Holdings
|
May 02, 2025 | BUY |
Strong Buy
+112.9% avg upside
22 analysts
|
$18.00
104.39% Upside
|
-13.1% |
|
ARAY
Accuray
|
May 01, 2025 | BUY |
Buy
+1689.3% avg upside
9 analysts
|
$6.00
1624.57% Upside
|
-68.9% |
|
HROW
Harrow Health
|
Nov 14, 2024 | BUY |
Strong Buy
+25.2% avg upside
12 analysts
|
$55.00
28.35% Upside
|
-4.8% |
|
LMAT
Lemaitre Vascular
|
May 03, 2024 | BUY |
Strong Buy
+7.8% avg upside
15 analysts
|
$75.00
20.21% Downside
|
+6.9% |
|
JYNT
Joint
|
Mar 08, 2024 | BUY |
Buy
+18.7% avg upside
9 analysts
|
$15.00
60.66% Upside
|
-7.6% |
|
DYNTQ
Dynatronics
|
Feb 09, 2024 | BUY |
Buy
+393333233.4% avg upside
4 analysts
|
$4.00
399999899.97% Upside
|
· |
|
NUWE
Nuwellis
|
Mar 01, 2023 | BUY |
Strong Buy
+16978.6% avg upside
7 analysts
|
$25.00
18626.55% Upside
|
-92.5% |
|
MDVLQ
MedAvail Holdings
|
Aug 12, 2022 | BUY |
Strong Buy
+224999900.0% avg upside
2 analysts
|
$200.00
199999900.09% Upside
|
· |
|
OPCH
Option Care Health
|
Jul 28, 2022 | BUY |
Strong Buy
+34.7% avg upside
20 analysts
|
$45.00
104.72% Upside
|
+0.7% |
|
MODD
Modular Medical
|
Apr 08, 2022 | BUY |
Strong Buy
+45.6% avg upside
3 analysts
|
$11.00
113.60% Upside
|
-57.4% |
|
HUMA
Humacyte
|
Apr 09, 2021 | BUY |
Strong Buy
+665.4% avg upside
11 analysts
|
$20.00
2063.65% Upside
|
-40.6% |
|
SNWV
Sanuwave Health
|
Sep 15, 2020 | BUY |
Strong Buy
+270.4% avg upside
3 analysts
|
$0.34
96.31% Downside
|
· |
|
DMAC
Diamedica Therapeutics
|
Aug 17, 2020 | BUY |
Strong Buy
+153.0% avg upside
12 analysts
|
$14.00
139.41% Upside
|
-31.0% |
|
ETON
Eton Pharmaceuticals
|
Jul 28, 2020 | BUY |
Strong Buy
-21.5% avg upside
8 analysts
|
$15.00
53.87% Downside
|
-3.5% |
|
AORT
Artivion
|
May 01, 2020 | BUY |
Strong Buy
+91.8% avg upside
8 analysts
|
$27.00
27.37% Upside
|
+31.6% |
|
NDRA
ENDRA Life Sciences
|
May 20, 2019 | BUY |
Strong Buy
+159.1% avg upside
3 analysts
|
$7.00
46.98% Upside
|
-43.2% |
|
CCRN
Cross Country Healthcare
|
Nov 02, 2018 | BUY |
Hold
+20.0% avg upside
15 analysts
|
$12.00
8.79% Downside
|
+14.3% |
|
USPH
US Physical Therapy
|
Dec 12, 2013 | BUY |
Strong Buy
+44.4% avg upside
12 analysts
|
$40.00
36.91% Downside
|
+25.7% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.